Business plan for the global pandemic influenza action plan to increase vaccine supply

Hhs pandemic influenza plan 2017

Groupings should match the anticipated vaccine supply in size and may need to be adjusted if vaccine supply projections change. It is important to have established, integrated, electronic surveillance systems and immunization registries with which to manage inventories, track vaccine uptake, monitor adverse events and inform vaccine effectiveness studies. Seasonal influenza vaccine - The process used to authorize already-approved seasonal influenza vaccines each year is modified from the full process for a new vaccine, because seasonal vaccine involves only a change in the influenza strain s used. This may include stockpiling in advance to ensure that supplies are readily available in the required quantities. There is a need for flexibility in dealing with just-in-time information and evolving recommendations and strategies for communicating changes. Such requests would be considered depending on the situation at the time of the request. For more information about vaccine storage and handling, see: National Vaccine Storage and Handling Guidelines for Immunization Providers Inventory management is essential to maximize available vaccine supplies and anticipate future needs. Extensive practical experience in dealing with outbreaks of avian influenza H5N1 virus in poultry and humans, in addition to pandemic preparedness and response exercises carried out in various countries, has led to a greater understanding of the issues that need to be addressed in pandemic preparedness. To prevent delays in release of the vaccine at time of pandemic, the pandemic vaccine supply contract stipulates that the Government of Canada will indemnify the manufacturer against any claims or lawsuits brought against it by third parties. The vaccine antigen and the adjuvant will be supplied in separate MDVs and will require mixing prior to administration. Pandemic vaccine is expected to play an important role in preventing illness and severe disease. Third, there has been growing attention to global health security following the adoption of the revised International Health Regulations IHR in , which provide a framework to address international public health concerns.

To facilitate planning at national and global levels, Phases and have been grouped to include common action points. For a new vaccine, it is not possible to detect all AEFI in pre-marketing studies, especially if they are very rare.

Language, culture, ethnicity and religious beliefs are aspects of Canada's diversity that may affect the provision of immunization in each jurisdiction. Assumptions provide a useful framework for planning but, while rooted in evidence to the extent possible, they should not be regarded as predictions.

The recommendations will categorize risk and age groups into various priority groupings, using the most effective strategies to address the national pandemic goals. Footnote 17 In Quebec, the number of GBS cases attributable to immunization primarily with adjuvanted vaccine was approximately two per one million vaccine doses, consistent with seasonal influenza vaccine.

In these circumstances, the use of seasonal influenza vaccine as well as pandemic vaccine would provide no additional benefit and its administration could consume valuable resources.

Evidence-informed decision-making is essential for the regulatory assessment of vaccine and the development of recommendations for pandemic vaccine use.

elements of a pandemic influenza plan

Establish criteria for reporting, protocols, quality indicators and training in each PT. Preparing your organization, staff, volunteers and clients for seasonal and pandemic flu.

Pandemic influenza plan

The focus of the post-pandemic period is restoration of normal health and social functions while addressing the long-term health and social impact of the pandemic. It is expected that NACI will undertake the prioritization exercise with the assistance of additional experts e. The federal government is responsible for: evaluating safety, efficacy and quality and providing regulatory authorization for the sale of influenza vaccines; acting as the focal point for vaccine manufacturers and international regulatory collaboration; providing regulatory authority to conduct clinical trials; negotiating with manufacturers and establishing contracts for the FPT purchase of vaccine for pandemic purposes; providing vaccine to those federal populations not covered by arrangements for PT provision; and conducting national monitoring of vaccine safety and effectiveness, overseeing special investigations and taking regulatory action as required. Footnote 11 Footnote 12 Footnote 13 Footnote 14 Pandemic vaccine had a good safety profile overall. Several steps are being taken in the interpandemic period to improve speed of production and vaccine effectiveness. Standard regulatory processes cannot be used for several reasons. Therefore, it is recommended that jurisdictions be prepared to deliver vaccine efficiently in remote and isolated communities.

The results may also lead to adjustment of prioritization recommendations if uptake is significantly lower or higher than projected.

Signals are investigated so that the cause can be assessed and action taken if appropriate, e.

Rated 5/10 based on 63 review
Download
EXECUTIVE SUMMARY